Sermorelin Before-and-After Blood Work: What to Test
Sermorelin and similar growth-hormone secretagogue peptides are largely used off-label, and there is no single medical-society guideline covering their monitoring the way there is for TRT or GLP-1 therapy. This page covers the small set of markers with an established basis for monitoring growth-hormone-axis activity: what to test, not whether to start, how to dose, or where to source the peptide.
A narrower panel than TRT or GLP-1, because the guideline basis is narrower
Sermorelin stimulates the pituitary to release growth hormone, which the liver then converts into IGF-1. IGF-1 is the standard blood marker used to track that downstream effect, but the wider use case, off-label growth-hormone-secretagogue therapy for adults, does not have the same guideline-published monitoring schedule TRT and GLP-1 therapy have.
This page is part of FixFirst's Peptides & Hormones section. Sermorelin and related growth-hormone-releasing peptides are approved for specific pediatric growth-hormone-deficiency indications; use in adults for other purposes is off-label, meaning it falls outside an FDA-approved indication and outside the kind of society-published monitoring schedule that exists for TRT and GLP-1 therapy. This page states that plainly rather than implying a guideline framework that doesn't exist for this use case.
There is a further caveat for anyone who competes under anti-doping rules. Sermorelin and related growth-hormone-releasing peptides are on the World Anti-Doping Agency (WADA) Prohibited List (class S2, peptide hormones and growth factors), prohibited at all times, both in and out of competition. For any athlete subject to anti-doping testing, a growth-hormone secretagogue is not recommended or advised, independent of any monitoring question this page covers.
Growth hormone itself is difficult to measure reliably from a single blood draw because it releases from the pituitary in pulses rather than at a steady level. IGF-1, produced by the liver in response to growth hormone, stays comparatively stable across the day and is the standard proxy marker used instead. The optimal IGF-1 level guide in FixFirst's Longevity section covers how longevity researchers Valter Longo and Peter Attia frame IGF-1 differently, useful context for reading a result, though that page is about longevity-protocol framing, not sermorelin monitoring specifically.
This page does not make an efficacy claim about sermorelin, does not cover anti-aging outcomes, and does not cover dosing, cycling, or sourcing. Anyone using or considering a growth-hormone secretagogue should have that conversation, and this testing framework, with the physician overseeing it.
What to test
Two clusters: the GH-axis marker itself, and baseline safety labs relevant to elevated growth-hormone activity generally.
Frequently asked questions
What blood tests should I get before starting sermorelin?
Why test IGF-1 instead of growth hormone directly?
Is sermorelin FDA-approved?
Is sermorelin banned in competitive sport?
Does sermorelin affect blood sugar?
References & Guidelines
- Molitch et al. — Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline (2011)
- Clemmons — Consensus Statement on the Standardization and Evaluation of Growth Hormone and IGF-1 Assays, Clinical Chemistry (2011)
- World Anti-Doping Agency — Prohibited List (S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics)
Once you have before-and-after results
Comparing two lab reports side by side is harder than it sounds when the layout or lab changes between draws. FixFirst reads both against the same clinical thresholds.
Compare your before-and-after results against the same clinical thresholds.
Upload your blood report and get a ranked read on every marker, adjusted for your context.
Analyze My Blood Test →